- Prostate Cancer
- Medical Oncology
- Renal Cell Carcinoma (RCC)
- Antibody-Drug Conjugates (ADCs)
- Circulating Tumor DNA (ctDNA)
- Minimal Residual Disease (MRD)
- Muscle Invasive Bladder Cancer (MIBC)
- Bladder Cancer
Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact.
Timestamps
Resources
More about this episode
The conversation covers the PROTEUS trial and perioperative intensification, RAMPART and Keynote-564 ctDNA findings in RCC, and new standards in perioperative bladder cancer treatment with EV plus pembrolizumab. Drs. Tan and Beckermann also discuss next-generation ADCs, pharmacogenomic toxicity considerations, and the promise of AI and ctDNA for patient selection and de-escalation strategies in advanced GU cancers.